Harnessing the Most Powerful Cells to Personalize Immune Medicine

The future of immune medicine holds promise for lasting and durable impact on many diseases; our high resolution systems are powering the development and further personalization of these curative medicines.

Introducing the IsoSpark

A personalized functional proteomics system for any lab.

Our Solutions

The Products Driving Our Superpowered Biology

Functional Immune Landscaping


Accelerate the ability to stratify patients using "super hero" immune biomarkers and accelerate path to clinic with higher potency immune therapies.

Intracellular Omics
Intracellular Signaling Omics


Identify adaptive signaling networks to accelerate development of targeted therapies to overcome resistance & metastases.

High-Plex Automation
High-plex Automated Immunoassays


For the first time, unleash super-powered and super-automated multiplexed proteomics in very low sample volumes for any lab to access insights right away.

Superpowered Biology Built on a Strong Foundation

Proteomics, Reimagined to uniquely detect our most powerful cells. 

The IsoLight: The entire ELISA proteomics workflow, sample to answer.

IsoSpeak Software: Same day visualizations and insights.

Areas of Interest

See how we can shift the paradigms in your programs

Through this research, we were able to highlight the important role a functionally versatile subpopulation of CAR-T cells may play in the fight against cancer. This could lead to new methods to optimize T-cell products.

Adrian Bot, MD
Vice President, Translation Sciences, Kite

The ability to easily perform single-cell proteomics provides a way to understand the complexity of the cellular response to immunotherapy and then to design and test new therapies to enhance efficacy.

Charles Sentman, PHD
Director, Center for Synthetic Immunity, Professor, Geisel School of Medicine, Dartmouth College

We see potential in utilizing IsoPlexis’ single-cell system to help provide deeper resolution into the functional impacts of our therapeutics… This collaboration will enable us to apply the sensitivity of this solution to further our understanding of patient-specific responses to our immune therapies.

Jon Zalevsky
Chief Scientific Officer, Nektar Therapeutics

“MD Anderson, IsoPlexis Link T-Cell Functionality to Immunotherapy Response in AML.”


The ability of the IsoLight to provide detailed analyses from very few cells is key, given that we are limited to small sample quantities of blood.

Petter Brodin, MD PHD
Associate Professor of Immunology at Karolinska Institute

Current assays that rely on a single-plex ELISA or even multiparametric flow cytometry don’t give you the level of resolution that the IsoPlexis platform can provide.

John Rossi
Director of Translational Sciences at Kite

As a cancer research center with a key focus on CAR-T and other cell therapies, we feel that IsoPlexis will enable us to better characterize response and potentially predict whether cancer patients will respond to CAR-T therapy before treatment.

Christine Brown
City of Hope

Quality assays are mainly descriptive with some objective parameters like cytokine production, cytotoxicity, and proliferation. Only recently, with PSI… can we start to differentiate products.

Marco L Davila
Moffitt Cancer Center